We compared the /?,-selective adrenoceptor antagonists bisoprolol and atenolol in a double-blind, randomized crossover study. After 4 weeks placebo phase, 59 patients with essential hypertension received either 10 mg bisoprolol or 50 mg atenolol once daily for 8 weeks, increased if necessary (target BP ^1 5 0 / 9 0 mmHg) to 20 and 100 mg, respectively, after 4 weeks. After a second placebo phase, crossover occurred to the alternative drug. We measured resting systolic and diastolic blood pressures and heart rate at 24 h post-dose baseline and after 4 and 8 weeks treatment. Both drugs significantly lowered systolic and diastolic blood pressures and heart rate at 8 weeks compared to baseline (all p<0.05). Bisoprolol reduced heart rate significantly more than atenolol ( p < 0 . 0 1 ) , but systolic and diastolic blood pressure changes were not different between the two drugs. There was no difference in patient acceptability of the drugs as assessed by visual analogue scale. Despite theoretical and circumstantial evidence to suggest superiority of bisoprolol over atenolol, no significant difference between the two was found except for greater heart rate reduction with bisoprolol.
Introduction
In the drug treatment of any disease, attention must be paid to the risk-benefit assessment. Ideally, a drug will be efficacious but produce no adverse effects. This is particularly important in the treatment of hypertension, which is largely an asymptomatic disease requiring life-time treatment.
In the treatment of hypertension, /2-adrenoceptor antagonists and thiazide diuretics are amongst the few classes of agent for which benefit has been shown in terms of morbidity even in mild hypertension. 1 Unfortunately, the MRC trial of mild hypertension demonstrated that the non-selective ^-antagonist propranolol was associated with a substantial adverse effect profile which resulted in the withdrawal of treatment in a significant number of patients. 2 It is generally assumed that /?,-selective antagonists such as atenolol retain anti-hypertensive efficacy but result in fewer deleterious effects, e.g. in bronchial asthma, peripheral vascular disease and insulin-dependent diabetes. However, they are associated with continuation of other ^-adrenoceptor antagonist related side-effects such as tiredness and cold peripheries which some patients find intolerable. Bisoprolol is a more recently developed /?,-antagonist which has been shown to have a greater degree of /?,-selectivity than atenolol. 3 " 5 However, this is relative rather than absolute. 6 ' 7 Early studies of its efficacy suggested that it might have greater antihypertensive effects than atenolol 8 ' 9 and anecdotal reports that it was well-tolerated even in patients who had suffered adverse events on atenolol, such as tiredness and cold peripheries, have also been attributed to bisoprolol's greater selectivity. 10 If bisoprolol was more efficacious than atenolol and/or had a reduced adverse reaction profile, then it might be considered to be the drug of choice within this class.
The aim of the present study was therefore to compare both the antihypertensive efficacy and tolerability of bisoprolol and atenolol, given in a doubleblind, randomized, chronic dosing, crossover regime to a cohort of patients with essential hypertension.
Methods
At the outset of the study, 80 patients were recruited and randomized into two groups (A and B) of 40 patients each, which determined the order of active treatment received. All patients had mild to moderate essential hypertension and had been withdrawn from previous treatment where necessary for at least 4 weeks prior to entry into the study. Patients were eligible to enter the study if, after this period, sitting diastolic blood pressures were in the range 95 to 125 mmHg (Phase V). Exclusion criteria were: secondary or accelerated hypertension; asthma; chronic obstructive pulmonary disease; symptomatic peripheral vascular disease; heart failure requiring diuretic therapy; insulin-dependent diabetes mellitus; recent myocardial infarction ( < 6 months); recent stroke ( < 3 months); clinically significant hepatic or renal impairment (serum creatinine>250 u.mol/1); known contraindications to, or previous lack of efficacy from bisoprolol or atenolol therapy. The study was approved by the Tayside Committee on Medical Research Ethics and all subjects gave written informed consent.
All patients had a complete physical examination, 12-lead electrocardiogram, full blood count, biochemical profile, urinalysis and weight recording prior to entry into the study. On each occasion during the study, blood pressure and heart rate recordings were made in the sitting position after a 5 min rest period, and again after 2 min standing. All recordings were made at trough, 24 h post-dose. Blood pressures were recorded using a Hawksley random zero sphygmomanometer and the mean of the two recordings in each position was used for analysis.
A 4 week placebo period followed, after which patients entered the first of two 8 week active treatment phases, providing all of the inclusion criteria and none of the exclusion criteria were satisfied. During the first active treatment phase, group A patients received bisoprolol 10 mg ('Monocor', Lederle Laboratories) plus placebo atenolol 50 mg, whereas group B patients received atenolol 50 mg plus placebo bisoprolol 10mg. All medications were taken orally on a once-daily basis at 0800 h. After 4 weeks active treatment, the doses of bisoprolol and atenolol were doubled to 20 mg and 100 mg, respectively, if the target blood pressure of ^ 150/90 mmHg had not been achieved. A further 4 week placebo phase preceded the second 8 week period of active treatment, during which patients received the alternative therapy in an identical fashion to the first active phase.
Heart rate, blood pressure, 12-lead electrocardiogram, body weight, tablet counts and visual analogue scales were recorded every 4 weeks. For the recording of visual analogue scores, patients were presented with a series of 12 ungraded scales 100 cm long, representing symptoms and mood (see Table 5 for parameters), and were asked to place a single mark on each line to indicate their present state of wellbeing. Individual scales were analysed alone and in addition a global score was derived for all 12 scales. Physical examination by a physician occurred every 4 weeks during active treatment, and a full blood count and biochemical profile were measured before and immediately after each active treatment phase.
Statistical methods
Assuming a standard deviation of 10 mmHg for sitting diastolic blood pressure, a total of 65 patients would be required to detect a 5 mmHg difference between the two treatments with 80% power at a significance level of 5% (two-sided). To allow for dropout, 80 patients were therefore recruited at the outset of the study. The primary endpoint was the change in blood pressure and heart rate recordings after 8 weeks of active treatment. Secondary endpoints were the number of patients reaching target blood pressure, the magnitude of the reduction in blood pressure, and the change in the visual analogue scores after 8 weeks active treatment. An efficacy analysis was performed, the efficacy population consisting only of eligible and evaluable patients who completed the study. The actual dose level was ignored during the analysis of all efficacy assessments, and the 8 week changes in blood pressure, heart rate and visual analogue scores were measured from the end of the preceding placebo period. A negative change therefore corresponded to a reduction in the assessment value. For the visual analogue scales, a negative change value indicated a move towards the positive end of the scale. Changes in blood pressure, heart rate and visual analogue scales were assessed using analysis of variance unless otherwise stated, with all treatment effects being adjusted for period effects before significance was tested, p values of <0.05 were considered statistically significant.
Results

Patient withdrawal
Of the 80 patients enrolled, 12 became ineligible to continue due to protocol violations, four withdrew during the run-in period due to adverse events, a further four withdrew prior to the second period of active treatment (two due to lack of efficacy, one due to an adverse event, one due to protocol violation), and one dropped out without apparent reason. This left 59 patients who completed the study, 34 of whom were in group A and 25 in group B.
Baseline measurements
No significant differences were present in baseline demographics between group A and group B patients, in respect of systolic or diastolic BP, heart rate, age, sex, weight and height ( Table 1 ). The median duration of hypertension was longer in group A patients (24 months) than in group B (9 months), although the difference was not statistically significant (p = 0.45, Mann-Whitney U-test). One quarter of patients had had hypertension for less than 4 months and half for less than 18 months. All patients except one were Caucasian.
At the secondary baseline, prior to the second active treatment period, a significantly lower sitting heart rate was found in group A compared with group B patients (74.6 + 1.9 vs. 81.6 + 1.8 bpm, respectively, p = 0.01, unpaired t-test). No significant differences were found between the two groups with respect to sitting systolic or diastolic blood pressure. Compared with pretreatment values, systolic and diastolic blood pressures were all slightly lower at the secondary baseline [mean change (mmHg) + SEM]: group A, systolic -2 . 0 + 1.3 (p = 0.07), diastolic -2 . 4 + 1.2 (p = 0.05); group B, systolic -1 . 6 + 2.7 (p = 0.55), diastoiic -2 . 5 + 1.3 (p = 0.07), (all paired t-tests). No significant changes in heart rate occurred compared with pretreatment values. Similar trends were found with standing blood pressures and heart rates. Individual visual analogue scores and the global score did not differ significantly between the two treatment groups at the first and second baselines. Due to the baseline differences, treatment effects were adjusted for period effect prior to significance testing being performed.
Blood pressure and heart rate responses
Both atenolol and bisoprolol significantly reduced sitting and standing systolic blood pressure, diastolic blood pressure and heart rate after 8 weeks of therapy, compared with the pretreatment baseline (all p<0.05, Table 2 ). Bisoprolol reduced both sitting and standing heart rate significantly more than atenolol, although no significant differences in systolic or diastolic blood pressure responses occurred between treatments (Table 3) . Bisoprolol and atenolol treatments did not differ significantly with respect to the numbers of patients reaching sitting target blood pressures after either 4 or 8 weeks of therapy (Table 4) . No significant differences between the two groups occurred in respect of the total number of patients requiring a dose increment. Overall, 30 patients (51%) required an increase in dose: 18 (53%) of the bisoprolol group and 12 (48%) of the atenolol group.
Visual analogue scales
No significant differences occurred between the two treatment groups with respect to changes in any of the 12 visual analogue scales or the global score (Table 5) .
Post-hoc power calculation
Despite the number of patients withdrawn, the smaller than anticipated standard deviations in blood pressure measurements had a favourable effect on the power calculation. Calculated in retrospect, the use of 59 patients enabled a 3.6 mmHg difference in sitting diastolic blood pressure to be detected at the 5% level with 80% power.
Adverse events
A total of 124 adverse events were experienced by 48 of the 70 patients who originally took at least one dose of active study medication. Twenty-eight of these events took place during the washout phase. Of the 96 events experienced during active treatment, Differences are calculated as bisoprolol effect minus atenolol effect, a negative difference therefore indicating that bisoprolol causes a greater reduction than atenolol. Results are expressed as mean differences and the associated 95% confidence interval for the difference. *Statistically significant. 43 were reported by 17 (26%) of the 66 patients who took bisoprolol, and the remaining 53 events were reported by 27 (39%) of the 69 patients who took atenolol. Fourteen (21%) of the 66 patients who took bisoprolol reported 22 adverse events considered to be directly drug-related, and 16 (23%) of the 69 patients who took atenolol reported 27 drug-related adverse events (see Table 6 ) Discussion This study did not detect any significant differences between bisoprolol and atenolol at the doses studied in terms of anti-hypertensive efficacy or tolerability. The only significant difference found was a greater reduction in sitting and standing heart rate using bisoprolol.
Resting heart rate is predominantly determined by vagal tone, since at rest in a normal individual the background level of sympathetic activity is low. Betaadrenoceptor antagonists have a variable effect on cardiac rate at rest, both within and between individuals, and effects on resting heart rate are a poor measure of /^-blockade. 11 Comparative studies of j5,-adrenoceptor antagonism are best performed under conditions of high sympathetic tone, such as on exercise. 12 Since exercise testing was not performed in the present study, we cannot relate the effects of bisoprolol on resting heart rate to greater /^-blocking potency, although this possibility cannot be excluded. Neither can the difference be attributed to increased /?,-selectivity, since this property was not formally investigated. Indeed, it is now wellrecognized that a substantial proportion of cardiac /J-adrenoceptors are of the /? 2 -subtype, 13 ' 14 which are also known to mediate chronotropic responses. 15 Overall /5-adrenoceptor antagonism, rather than /?,-selectivity per se, therefore determines the degree of sympathetic blockade obtained. Since the population studied were patients with essential hypertension rather than normal subjects, it is likely that in many patients increased noradrenergic tone played a key role in the genesis of their raised blood pressure.
These patients may be expected to respond well tô -blocking drugs in general, and perhaps particularly so to /?, -selective agents.
The central effects of antihypertensive agents are also very important, since hypertension is a largely asymptomatic condition and patients continue to pursue normal working and leisure activities. Adverse effects on psychomotor function may affect compliance with medication and may be of particular importance to other susceptible individuals such as the elderly, or those whose work involves skilled activity. /?-Adrenoceptor antagonists have been shown to produce small but significant adverse effects on the electroencephalogram and on psychomotor performance. These changes are found using hydrophilic and lipophilic agents and both the /?,-selective and non-selective antagonists. 16 ' 17 In the present study, no significant changes occurred in visual analogue scores using either bisoprolol or atenolol, and the two agents did not significantly differ from each other in this respect. It must be stressed, however, that the lack of change in visual analogue scores does not exclude significant adverse effects on psychomotor performance or electroencephalography, since such effects may occur in the absence of subjective awareness. 18 In choosing between drugs of the same class, clinicians should be aware that scientific comparative data and not theoretical, anecdotal or circumstantial evidence are required. The present study has found no evidence that bisoprolol has any clinical advantages over atenolol.
In summary, this double-blind, randomized, crossover study has demonstrated no significant differences in the antihypertensive efficacy or tolerability of bisoprolol and atenolol when given in standard clinical doses. Bisoprolol produced a significantly greater reduction in sitting and standing heart rate, although the significance of this finding is uncertain. Differences between treatments on overall 24 h blood pressure control cannot be excluded and ambulatory monitoring is required to further clarify this issue. Under rigorous scientific conditions, we have therefore found no convincing evidence that the theoretical advantages of bisoprolol over atenolol translate into any measurable clinical benefit.
